Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial

PURPOSE: Despite therapeutic advances, patients with multiple myeloma (MM) continue to experience disease relapse and treatment resistance. The gene ABCB1 encodes the drug transporter P-glycoprotein, which confers resistance through drug extrusion across the cell membrane. Lenalidomide (Len) is excr...

Descripción completa

Detalles Bibliográficos
Autores principales: Jakobsen Falk, Ingrid, Lund, Johan, Gréen, Henrik, Gruber, Astrid, Alici, Evren, Lauri, Birgitta, Blimark, Cecilie, Mellqvist, Ulf-Henrik, Swedin, Agneta, Forsberg, Karin, Carlsson, Conny, Hardling, Mats, Ahlberg, Lucia, Lotfi, Kourosh, Nahi, Hareth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754426/
https://www.ncbi.nlm.nih.gov/pubmed/29177954
http://dx.doi.org/10.1007/s00280-017-3481-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754426/
https://www.ncbi.nlm.nih.gov/pubmed/29177954
http://dx.doi.org/10.1007/s00280-017-3481-8

Ejemplares similares